BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 7533866)

  • 1. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
    Verma UN; Bagg A; Brown E; Mazumder A
    Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
    Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
    Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of various cytokines with interleukin 2 in the generation of killer cells from human bone marrow: application in purging of leukemia.
    Charak BS; Agah R; Gray D; Mazumder A
    Leuk Res; 1991; 15(9):801-10. PubMed ID: 1921458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
    Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
    Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ; Chen HC; Peng XH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
    Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
    J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2-activated cord blood mononuclear cells.
    Derzic S; Slone V; Sender L
    Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.